Skip to main content

Table 1 Subject characteristics

From: A modified regimen of extracorporeal cardiac shock wave therapy for treatment of coronary artery disease

  Control group ( n = 14) Group A ( n = 20) Group B ( n = 21) P
Age, years 67.9 ± 7.8 62.7 ± 12.0 64.1 ± 9.8 0.337
Sex, male (%) 12 (85.7) 18 (90) 17 (81) 0.882
BMI, kg/m2 24.0 ± 3.2 24.5 ± 2.8 23.4 ± 2.7 0.513
Disease history, years 3 (2, 5) 4 (2.0 , 7.8) 2 (1 , 2) 0.006*
Smokers 6 (42.9) 7 (35.0) 9 (42.9) 0.884
Underwent stenting 11 (78.6) 14 (70) 9 (42.9) 0.080
Comorbid conditions     
Essential hypertension 10 (71.4) 13 (65.0) 16 (76.2) 0.708
Diabetes mellitus 4 (28.6) 7 (35.0) 4 (19.0) 0.553
Hyperlipidemia 6 (42.9) 4 (20.0) 4 (19.0) 0.259
COPD 1 (7.1) 0 (0) 0 (0) NA
Chronic renal failure 0 (0) 1 (5.0) 2 (9.5) NA
Atrial fibrillation 0 (0) 1 (5.0) 0 (0) NA
Ulcerative colitis 0 (0) 0 (0) 1 (4.8) NA
Condition     0.383
Stable angina pectoris 2 (14.3) 0 (0) 0 (0)  
Old myocardial infarction 8 (57.1) 13 (65.0) 14 (66.7)  
Unstable angina pectoris 4 (28.6) 7 (35.0) 7 (33.3)  
Medical therapy     
Anti-platelet agents 9 (64.3) 11 (55.0) 14 (66.7) 0.774
Aspirin 12 (85.7) 17 (85.0) 19 (90.5) 0.883
Angiotensin-converting enzyme inhibitors 7 (50.0) 7 (35.0) 8 (38.1) 0.732
Angiotensin receptor blocker 1 (7.1) 4 (20.0) 4 (19.0) 0.659
β-blockers 13 (92.9) 18 (90.0) 18 (85.7) 0.872
Calcium channel blockers 4 (28.6) 6 (30.0) 11 (52.4) 0.281
Statin 13 (92.9) 18 (90.0) 17 (81.0) 0.675
Nitrates 4 (28.6) 8 (40.0) 9 (42.9) 0.727
Diuretics 2 (14.3) 3 (15.0) 3 (14.3) 1.000
Oral hypoglycemic agents 3 (21.4) 2 (10.0) 3 (14.3) 0.648
Insulin 2 (14.3) 2 (10.0) 1 (4.8) 0.623
Patients who experienced re-infarction 1 (7.1) 0 (0) 0 (0) NA
Re-hospitalization     0.461
Once 4 (28.6) 2 (10) 2 (9.5)  
Twice 1 (7.1) 1 (5) 1 (4.8)  
Thrice 1 (7.1) 1 (5) 0 (0)  
Mortality 0 (0) 1 (5.0) 0 (0) NA
Location of ischemic target area     
Ventricular septum 11 (78.6) 11 (55.0) 12 (57.1) 0.365
Anterior wall 2 (14.3) 4 (20) 4 (19) 1.000
Inferior wall 5 (35.7) 11 (55.0) 14 (66.7) 0.194
Posterior wall 1 (7.1) 3 (15.0) 3 (14.3) 0.771
Lateral wall 2 (14.2) 3 (15.0) 0 (0) 0.161
Number of shock wave treatment (9 times/per treatment course) NA 2 (1, 2.8) 2 (1, 2.5) 0.904
Duration of treatment interval, month NA 5 (4, 6.5) 4 (4, 5.5) 0.231
  1. COPD: chronic obstructive pulmonary disease.
  2. Data are presented as mean ± standard deviation, number (%), or median (IRQ) as described in the statistical analysis methods.
  3. * P < 0.05, indicated significant difference was identified among control group, group A, and group B.
  4. NA, not assessed.